Tulex Pharmaceuticals

What Tulex Pharmaceuticals does

Tulex Pharmaceuticals, Inc. is a U.S.-based, technology-driven specialty pharmaceutical company headquartered in Cranbury, New Jersey. Founded in 2014, Tulex operates a 35,000 sq. ft. FDA-inspected cGMP facility that delivers end-to-end pharmaceutical development and manufacturing services, ranging from early-phase development and validation through clinical batch production, regulatory filing support, commercial manufacturing, and packaging. The company's technology foundation is three proprietary oral drug delivery platforms: BEST (Bio-availability Enhancement Sizing Technology), a vertical wet milling process that produces nano-sized particles to enhance GI absorption and bioavailability of poorly soluble compounds; GREAT (Gradient Release Enabling Advanced Technology), a coating technology that produces programmed drug concentration gradients in film matrices for chronotherapeutic and zero-order or pulsatile release; and MAXIPHERE, a high-impact pelletizing process for high-density drug loading with shorter processing times and scalable extended-release output. These platforms are used both as service-differentiation assets for CDMO clients and as the formulation engine for proprietary NDA (505(b)(2)) and ANDA product development, including products commercialized via strategic partnerships.

Tulex's revenue model is multi-pronged: (1) contract development and manufacturing services (CDMO) sold on a professional-services/basis to emerging and established pharmaceutical companies; (2) one-time license-based revenue from proprietary NDA and ANDA product development; and (3) royalty/licensing income from co-developed products via joint ventures, the most material being ART-501 (also TLX-032), an oral liquid extended-release formulation developed with Artisan Therapeutics (a wholly owned subsidiary of NASDAQ-listed Aardvark Therapeutics) for the autism spectrum disorder indication. Pricing is quote-based B2B and is not publicly disclosed. Distribution is direct in the U.S. and through strategic commercialization partners for international markets. The company is a wholly owned subsidiary of Easywell Biomedicals (TPEX: 1799.TWO), a publicly listed Taiwanese parent.

Tulex differentiates on a regulated, integrated service model, a leadership team with 70+ combined years of pharmaceutical experience and a track record of dozens of FDA approvals across NDA, ANDA, 505(b)(2), 510(k), and PMA pathways, and a portfolio of 40+ authored patents concentrated in drug delivery. The company complies with cGMP, 21 CFR Parts 210 and 211, DEA (Schedule III-V), EPA, and OSHA standards. As of late 2025, Tulex had reported Phase 2a results for ART-501 (4 of 6 participants showing meaningful clinical benefit and a clean safety profile), representing the most significant clinical pipeline milestone to date and the primary forward-looking value-creation event. Customer concentration evidence is limited: no public client logos are disclosed, and disclosed headcount sits in the 1-10 range, which constrains the scale of any single CDMO relationship.

Name

Tulex Pharmaceuticals

Legal name

Tulex Pharmaceuticals, Inc.

Website

https://tulexpharma.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Tulex Pharmaceuticals is a U.S.-based specialty pharmaceutical CDMO in Cranbury, NJ that uses proprietary BEST, GREAT, and MAXIPHERE drug delivery platforms to provide formulation development, analytical services, and cGMP manufacturing to emerging pharma clients, and co-develops specialty products such as ART-501 for autism.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development and Manufacturing (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Pharmaceutical contract manufacturing
• Drug delivery technologies
• Oral solid dosage forms
• CDMO services
• Generic drug development

Headquarters

HQ city

Cranbury

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services (CDMO): Provides comprehensive pharmaceutical development and manufacturing services to clients including early-phase development, analytical method validation, clinical batch manufacturing, scale-up, commercial manufacturing, and packaging. Revenue generated through service contracts and product development fees.
2. NDA and ANDA Product Development: Develops proprietary products including NDA (505(b)(2)) and ANDA products using existing molecules in new dosage forms or routes of administration. Products commercialized via strategic partnerships.
3. Joint Venture Product Revenue (ART-501): Revenue from co-developed drug products through joint ventures. ART-501 is a proprietary oral liquid extended-release formulation developed with Artisan Therapeutics for autism spectrum disorder treatment.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Tulex Pharmaceuticals is a contract development and manufacturing organization (CDMO) that develops and manufactures oral-dosage pharmaceutical products (tablets, capsules, liquid extended-release formulations) for emerging and established pharmaceutical clients. Services span early-phase development, analytical method validation, regulatory filing support, clinical batch manufacturing, scale-up, commercial manufacturing, and packaging using proprietary drug delivery technology platforms (BEST, GREAT, MAXIPHERE). The company also develops its own NDA (505(b)(2)) and ANDA products in new dosage forms and participates in joint-venture product development (e.g., ART-501/TLX-032 with Artisan Therapeutics).

Product overview

Tulex Pharmaceuticals is a technology-driven specialty pharmaceutical company that develops and manufactures innovative drug products for oral administration. The company operates through three proprietary drug delivery technology platforms: BEST (Bio-availability Enhancement Sizing Technology) for nanoparticle formulation, GREAT (Gradient Release Enabling Advanced Technology) for programmed drug release, and MAXIPHERE (Innovative Pelletizing Technology) for high-dose drug loading. These platforms enable the development of NDA and ANDA products of existing molecules in new dosage forms or via new routes of administration. The company also collaborates on product development through joint ventures, such as ART-501 with Artisan Therapeutics for autism spectrum disorder treatment. Tulex provides comprehensive services from early-phase development through commercial manufacturing, including analytical method validation, regulatory submissions, clinical batch manufacturing, and packaging.

Differentiator

Problem solved

Functional benefit

Products and services

• Contract Development and Manufacturing (CDMO) Services End-to-end pharmaceutical development and manufacturing services for emerging and established pharma clients, covering early-phase development, validation, regulatory filing, clinical batch manufacturing, scale-up, commercial manufacturing, and packaging for oral dosage forms. Delivered from Tulex's 35,000 sq. ft. FDA-inspected cGMP facility in Cranbury, NJ.
• NDA (505(b)(2)) and ANDA Product Development Proprietary drug product development program using Tulex's BEST, GREAT, and MAXIPHERE delivery platforms to develop new dosage forms and routes of administration of existing molecules, including NDA (505(b)(2)) and ANDA products, commercialized through strategic partners in the U.S. and other major markets.
• ART-501 (formerly ARD-501 / TLX-032) Proprietary oral liquid extended-release formulation of an existing, well-tolerated opioid receptor modulating drug, developed through a joint venture between Tulex and Artisan Therapeutics for treatment of autism spectrum disorder (ASD). Reported Phase 2a results showed 4 of 6 participants experienced meaningful clinical benefit with no serious adverse events.

Quantifiable outcome

• Four out of six participants showed meaningful signs of clinical benefit in Phase 2a trial for ART-501 in ASD patients

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Artisan TherapeuticscoreStrategic or Co-development PartnerJoint venture between Tulex and Artisan Therapeutics for development of ART-501 (also known as TLX-032), a proprietary oral liquid extended-release formulation for autism spectrum disorder. Artisan Therapeutics is a wholly owned subsidiary of Aardvark Therapeutics (NASDAQ: AARD). Phase 2a clinical trial showed positive results with 4 of 6 participants demonstrating meaningful clinical benefit.
• Easywell BiomedicalscoreOthersTulex Pharmaceuticals is a wholly owned subsidiary of Easywell Biomedicals, a publicly listed company in Taiwan (TPEX: 1799.TWO).
• Aardvark TherapeuticsminorOthersAardvark Therapeutics (NASDAQ: AARD) owns Artisan Therapeutics, the joint venture partner for ART-501 development. Artisan Therapeutics is developing ART-501 through a joint venture with Tulex.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tulex Pharmaceuticals